Published in final edited form as:

Hypertension. 2015 April ; 65(4): 793–799. doi:10.1161/HYPERTENSIONAHA.114.05037.

A Novel Retro-Inverso Peptide Inhibitor Reverses Angiotensin Receptor Autoantibody-Induced Hypertension in the Rabbit

Hongliang Li,

Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

David C. Kem*,

Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Ling Zhang,

Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Bing Huang,

Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Campbell Liles,

Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Alexandria Benbrook,

Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Hariprasad Gali,

Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Vineet Veitla,

Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Benjamin J. Scherlag,

Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Madeleine W. Cunningham, and

Correspondence to Xichun Yu, MD, Endocrinology and the Heart Rhythm Institute, University of Oklahoma Health Sciences Center, TCH 6E103, 1200 Everett Dr, Oklahoma City, OK 73104; Tel: 405-271-5896, Fax: 405-271-7455, xichun-yu@ouhsc.edu.

*D.C.K. and X.Y. served as co-senior authors.

Disclosures: D.C.K. as inventor has submitted US Patent No. 7,348,305, Application No. PCT/US14/28362 regarding the RID peptide used in this manuscript.

Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Xichun Yu*

Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, OK

Abstract

Activating autoantibodies to the angiotensin II type 1 receptor (AT1R) have been implicated in hypertensive disorders. We investigated whether AT1R antibodies produced in immunized rabbits will activate AT1R and contribute to hypertension by a direct contractile effect on the vasculature; and if they can be blocked by a novel decoy peptide. A multiple antigenic peptide containing the AT1R epitope AFHYESQ, which is the receptor binding epitope of AT1R-activating autoantibodies, was used to immunize 6 rabbits. AT1R antibody activity was analyzed in AT1R-transfected cells, and their contractile effects were assayed using isolated perfused rat cremaster resistance arterioles. A retro-inverso D-amino acid (RID) epitope-mimetic peptide was tested for AT1R antibody inhibition in vitro and in vivo. All immunized animals produced high AT1R antibody titers and developed elevated blood pressure. No changes in measured blood chemistry values were observed after immunization. Rabbit anti-AT1R sera induced significant AT1R activation in transfected cells and vasoconstriction in the arteriole assay, both of which were blocked by losartan and the RID peptide. A single intravenous bolus injection of the RID peptide (1 mg/kg) into immunized rabbits dropped the mean arterial pressure from 122 ± 11 mmHg to 82 ± 6 mmHg. Rabbit anti-AT1R sera partially suppressed angiotensin II-induced contraction of isolated rat cremaster arterioles, and the pressor response to angiotensin II infusion was attenuated in immunized animals. In conclusion, AT1R-activating autoantibodies and the RID peptide respectively have important etiological and therapeutic implications in hypertensive subjects who harbor these autoantibodies.

Keywords

retro-inverso peptide; activating autoantibodies; angiotensin II type 1 receptor; hypertension; vasoconstriction; rabbit

Introduction

Hypertension is a major risk factor for cardiovascular and renal disease with high morbidity and mortality. It affects approximately 50 million people in the United States and imposes a tremendous health and economic burden on society.¹ Despite the availability of numerous antihypertensive medications, the control of blood pressure remains inadequate in many cases. The causation of essential hypertension, the most common form of hypertension, is complex and incompletely understood. Multiple mechanisms have been proposed to contribute to its pathogenesis. Recent evidence from both clinical and basic studies suggests that hypertension may have an autoimmune basis.^{2, 3} Autoantibodies to the angiotensin AT1 receptor (AT1R) have been described in patients with preeclampsia,⁴ malignant and refractory hypertension,^{5, 6} renal allograft rejection,⁷ and in subjects with primary

aldosteronism.^{8, 9} These autoantibodies demonstrated agonistic activity in vitro, and their titers correlated with disease severity.¹⁰ More importantly, transfer of AT1R-activating autoantibodies (AT1R-AAb) from preeclampsia patients to non-pregnant and pregnant mice respectively produced hypertension and a preeclampsia-like phenotype, both of which were prevented by the AT1R blocker losartan.¹¹ Agonistic autoantibodies to the α 1-adrenergic receptor (α 1AR) have also been documented in patients with essential and refractory hypertension.¹²⁻¹⁴ In animal models, immunization with α 1AR-derived receptor peptide induced cardiac remodeling and diastolic dysfunction associated with α 1AR-activating antibodies developed in the rats.^{15, 16} However, these α 1AR-immunized animals failed to develop hypertension.

The heptapeptide sequence AFHYESQ from the second extracellular loop (ECL2) of AT1R has been identified as the functional epitope of AT1R-AAb from patients with preeclampsia.⁴ We have used a multiple antigenic peptide containing this epitope sequence to immunize the rabbit and demonstrated for the first time an AT1R-AAb-induced hypertensive phenotype in immunized animals. The present study utilized this animal model of autoimmune hypertension to investigate the therapeutic potential of a newly designed retro-inverso D-amino acid (RID) decoy peptide that specifically targets the AT1R-AAb. RID peptides, in which L-amino acids are substituted for D-amino acids in a reversed sequence, assume a side chain topology similar to that of their parent peptides but with inverted amide peptide bonds. They mimic the structure and antigenicity of the parent L-peptide but are resistant to protease degradation.¹⁷ Here we demonstrate that the RID peptide can effectively block the effects of AT1R-AAb both in vitro and in vivo.

Methods

This study protocol was approved by the Institutional Animal Care and Use Committee of the Oklahoma City Veterans Affairs Medical Center and Oklahoma University Health Sciences Center, and conforms to international standards for animal safety and comfort.

Experimental Procedures

Six New Zealand white rabbits (2.5-3 kg), fed on standard rabbit chow, were immunized with 1 mg of a multiple antigenic peptide containing the AT1R epitope sequence AFHYESQ (GenScript, Piscataway, NJ) in 0.5 ml of complete Freund's adjuvant. The animals were boosted with the same peptide plus incomplete Freund's adjuvant (1 mg/0.5 ml) at 2 and 4 weeks. At 6 weeks, the rabbits were treated with an intravenous bolus injection (1 mg/kg) of an epitope-mimicking RID peptide (d-QSEYHFA, GenScript). Under anesthesia (ketamine/xylazine 35 mg/5 mg/kg), the rabbit central ear artery was cannulated and the catheter connected to a pressure transducer (Edwards Lifesciences, Irvine, CA). Arterial blood pressure was measured at pre-immune and post-immune (6 weeks after immunization) before and 90 minutes after RID peptide injection. To determine the acute effect of Ang II on blood pressure before and after immunization, increasing doses of Ang II (10, 100, and 500 ng/kg) were injected intravenously at 5-min intervals using an infusion pump, and the blood pressure response at each dose was recorded. Each rabbit served as its own control.

Pre- and post-immune sera were obtained from all animals for ELISA and activity assays of the expected antibodies generated during immunization.

Peptide Stability to Proteolysis

The stability of the peptides in serum was assessed by incubation of the peptides (500 µg) in human serum (500 µL) at 37°C. After a specific time, a sample (200 µL) was added to a MW 10K cutoff centrifugal filter and centrifuged for 15 min at 12,000 rpm. A sample of filtrate (100 µL) was injected into a high pressure liquid chromatography (HPLC) system (Beckman, Pasadena, CA) for analysis.

Blood Chemistry Analysis

Arterial blood samples were analyzed with a portable analyzer (E3+ cartridges, VetScan i-STAT Handheld Analyzer, Abaxis Veterinary Diagnostics, Union City, CA) for immediate measurement of sodium, potassium, chloride, hematocrit and hemoglobin.

ELISA

Antibodies produced in the sera were detected by ELISA. Briefly, microtiter plates were coated with the AT1R multiple antigenic peptide at 10 µg/ml. To determine antibody titer, sera were diluted 1:10,000 and thereafter diluted 2-fold. Goat anti-rabbit IgG conjugated with alkaline phosphatase and its substrate para-nitrophenyl-phosphate 104 were used to detect antibody binding. Titers were determined as the highest dilution with an optical density (OD) value of 0.10 at 60 minutes.

Cell-Based AT1R Activation Assay

Agonist-like autoantibody activity was measured in AT1R-transfected Chinese hamster ovary (CHO) cells using the PathHunter eXpress β-arrestin GPCR assay kit (DiscoverX, Fremont, CA) as previously described.⁹ Briefly, 10,000 AT1R-CHO cells were dispensed into each well of a 96-well culture plate and incubated for 48 hours. Assay buffer containing rabbit sera (1:20 ~ 1:500) in the presence and absence of AT1R blocker losartan (10 µM) were then added and incubated for 90 minutes. Preincubation of rabbit anti-AT1R sera with an excess of the RID peptide was also tested for neutralization studies. Ang II (100 nM) was used as a positive control. All samples were tested in triplicate. Following sample treatment, PathHunter detection reagents were added and the luminescence signal quantitated to determine β-arrestin recruitment levels. The β-arrestin values are expressed as percentage of buffer baseline to normalize the individual data.

Contractility Assay

Antibody pressor activity was assayed using an isolated rat cremaster arteriole assay as previously described.⁹ Briefly, arteriolar segments were microdissected from the cremaster muscle of anesthetized rats and cannulated with glass micropipettes. After equilibration and development of steady-state myogenic tone, the arterioles were perfused with rabbit sera (1:10 - 1:500). The AT1R blocker losartan (10 µM) was then added to the perfusate and the effect on vessel diameter was recorded. The effect of rabbit anti-AT1R sera preincubated with the RID peptide was also tested. A dosage response curve for Ang II (10^{-10} ~ 10^{-5} M) in

the absence and presence of rabbit anti-AT1R sera (1:100) was constructed to examine the impact of AT1R-AAb on Ang II-induced contractile response. Measurements of vessel diameter were made using a video edge detector. Data are reported as percentage of baseline diameter to normalize each response.

Statistical Analysis

Data are presented as mean $\pm$ SEM. Comparison between two groups was performed by paired or unpaired Student's t-test as appropriate. One-way ANOVA followed by Newman-Keuls post hoc test was used for multiple group comparisons. Statistical significance was set at $p < 0.05$.

Results

Development of a Proteolytically Resistant Peptidomimetic

We designed a RID peptide based on the known AT1R epitope sequence AFHYESQ. This enantiomer peptide, made of all D-amino acids in a reversed sequence (d-QSEYHFA), maintains a side chain topology similar to that of the original L-amino acid peptide, thus mimicking the molecular structure of the peptide AFHYESQ (Figure 1A and 1B). The stability of the RID peptide in human serum was analyzed by HPLC to quantify the intact peptide remaining in solution. In comparison to the L-amino acid peptide AFHYESQ, which was rapidly degraded with complete loss of integrity by 45 min, the RID peptide remained 100% intact at 2 hrs and 80% intact at 24 hrs (Figure 1C and 1D).

Inhibition of AT1R-AAb-Induced Hypertension by RID Peptide

The mean arterial pressure (MAP) was measured at pre-immune baseline and 6 weeks after initial immunization. Each rabbit served as its own control. The MAP was significantly elevated after immunization with the AT1R epitope peptide AFHYESQ (pre-immune: 73 ± 5 vs. post-immune: 122 ± 11 mmHg, $p < 0.01$) (Figure 2A). The post-immune heart rate was also significantly increased compared to baseline (pre-immune: 137 ± 7 vs. post-immune: 165 ± 8 bpm, $p < 0.01$) (Figure 2B). A single bolus injection of the RID peptide at 6 weeks effectively suppressed the elevated MAP (post-immune: 122 ± 11 vs. post-RID: 82 ± 6 mmHg, $p < 0.05$, Figure 2A) and heart rate (post-immune: 165 ± 8 vs. post-RID: 140 ± 8 bpm, $p < 0.05$, Figure 2B) to their baseline levels. A similar study at 12 weeks demonstrated a sustained suppression of blood pressure elevation in the absence of any further interventions (data not shown).

Blood levels of sodium, potassium, chloride, hematocrit and hemoglobin in all rabbits were analyzed, and no significant differences in any of the measured parameters were detected between the pre-immune and post-immune state (Table 1).

Inhibition of AT1R-AAb Activity by RID Peptide in Vitro

All 6 rabbits developed high antibody titers to AT1R ranging from 1:640,000 to 1:1.28 million after peptide immunization. The ability of rabbit sera to stimulate AT1R activation was tested in transfected CHO cells in vitro. The post-immune sera demonstrated a dose-response effect on AT1R activation with significant activity at dilutions ranging from 1:20

to 1:200 (Figure 3A). The post-immune sera (1:100) induced a significant increase in AT1R activity over the pre-immune sera ($250\pm 17\%$ vs. $131\pm 9\%$, $p<0.01$), which was effectively blocked by the AT1R blocker losartan ($10\text{ }\mu\text{M}$) and by preincubation with the RID peptide (from $250\pm 17\%$ to $158\pm 15\%$ and $150\pm 11\%$, respectively, $p<0.01$) (Figure 3B). No significant AT1R activity was found with the pre-immune sera compared to buffer baseline.

The vasoconstrictive response to rabbit anti-AT1R sera was examined using a rat cremaster arteriolar assay. There was a significant dose effect on vasoconstriction for the post-immune sera with maximal activity at 1:10 dilution (Figure 4A). Significant contractile activity was observed at dilutions ranging from 1:10 to 1:125. The post-immune sera (1:100)-induced arteriole contractility was largely suppressed by losartan ($10\text{ }\mu\text{M}$) and by preincubation with the RID peptide (from $87\pm 3\%$ to $97\pm 3\%$ and $95\pm 3\%$, respectively, $p<0.01$) (Figure 4B). No significant contractile activity was observed in the pre-immune sera.

Allosteric Effect of AT1R-AAbs on Ang II-Mediated Pressor Response

To determine whether AT1R-AAbs would alter the hemodynamic responses produced by Ang II injections, we infused increasing doses (10, 100 and 500 ng/kg) of Ang II into rabbits before and after immunization and compared their MAP values. Ang II infusion caused transient, dose-dependent increases in MAP in both pre-immune and post-immune states; however, the magnitude of the pressor response in the post-immune state was significantly less than that in the pre-immune state (Figure 5A). At doses of 100 and 500 ng/kg, Ang II caused an increase in MAP of 17.8 ± 2.5 and 23.3 ± 2.7 mmHg respectively in the post-immune state compared to 31.6 ± 2.8 and 51.5 ± 3.8 mmHg respectively in the pre-immune state ($p<0.01$). The impact of rabbit anti-AT1R sera (1:100) on Ang II-induced vasoconstriction was also examined using the cremaster arteriole assay. As shown in Figure 5B, the contractility curve for Ang II ($10^{-10}\sim 10^{-5}\text{ M}$) was shifted significantly to the right in the presence of anti-AT1R sera compared to control, demonstrating similar negative allosteric effect of AT1R-AAbs as observed in vivo.

Discussion

The renin-angiotensin system is integrally involved in cardiovascular and renal homeostasis; therefore the presence of circulating Ang II-like autoantibodies would be expected to play a role in altered regulation of blood pressure and cardiac function. AT1R autoantibodies have been implicated in several types of hypertensive disorders. However, no models have been established to provide direct evidence linking hypertension to these autoantibodies as opposed to the indirect or observed associations described clinically. Wenzel et al used the heptapeptide AFHYESQ to immunize the rabbit, which induced production of AT1R-AAbs.¹⁸ The short term passive transfer of the rabbit AT1R-AAbs alone in their pregnant rats did not alter the rat blood pressure. However co-infusion of relatively low dosages of Ang II along with the AT1R-AAbs did raise the blood pressure in their rat model of preeclampsia. The impact of AT1R-AAbs alone on blood pressure in their immunized rabbits was not reported. When we immunized our rabbits with this same peptide, all animals produced AT1R-AAbs that functioned similarly to those observed in humans; and all animals demonstrated significantly elevated blood pressure. In contrast to Wenzel et al, these AAbs

caused the animals to be resistant to Ang II infusion. These data suggest that there are inherent differences between the non-pregnant and pregnant responsiveness to both Ang II and AT1R-AAb. Our model, therefore, provides a valuable tool for in vivo studies of pathophysiology and treatment of autoantibody-mediated hypertension without the need for coexistent infusion of Ang II.

Investigation of therapeutic strategies that target activating autoantibodies in cardiovascular disease has primarily focused on cardiomyopathy associated with autoantibodies to the β 1-adrenergic receptor (β 1AR). These include elimination of cardiomyopathic autoantibodies by immunoadsorption^{19, 20} and use of specific peptides or oligonucleotides as autoantibody scavengers.²¹⁻²³ Orthosteric receptor antagonists are questionable since they also block the normal ligand and thereby impair the normal physiological responses. Small peptide inhibitors as therapeutic agents have several advantages over other small molecules, including high specificity and low levels of toxicity and immunogenicity.²⁴ The use of a modified β 1AR ECL2 cyclic peptide to neutralize β 1AR-activating autoantibodies has been advocated and is under limited trial in Europe.²⁵ In the present study, we tested a proteolytically stable RID peptide designed to target AT1R-AAb. This peptide demonstrated effective antibody-blocking effect both in vitro and in vivo. It inhibited AT1R-AAb-stimulated AT1R activation in cultured cells, blocked AT1R-AAb-induced contraction of isolated resistance arterioles, and reversed the elevated blood pressure for at least three months in AT1R-immunized animals. RID peptides offer the advantage of increased biological half-life and bioactivity over the natural L-peptides. This approach has been used effectively for development of peptide inhibitors as a potential novel treatment for Alzheimer's disease²⁶ and lupus.²⁷ Compared to the cyclic peptide approach that requires complex synthesis and uses an entirely different means of protection of the peptide structure, this construct is relatively simple and can be easily adapted to targets of other autoantibodies and administered orally.

We have previously reported AT1R-AAb have a variable effect on different tissues. The AT1R-AAb harvested from our rabbits by themselves demonstrated a contractile effect on an isolated arteriole in vitro which is compatible with their hypertensive effects in vivo. AT1R-AAb harvested from patients with primary aldosteronism were capable of stimulating aldosterone production in vitro and presumably had a similar effect in vivo.⁹ The high sodium intake in our rabbits led to suppressed plasma renin activity values in the basal state. The small number and variability of aldosterone values obtained in the post-immune state prevented us from drawing a significant conclusion about stimulation of aldosterone production. The small drop in serum potassium that was observed was not significant. We are planning more detailed studies on the metabolic consequences of AT1R immunization.

Allosteric autoantibodies may express variable modulatory effects on the action of the orthosteric “natural” ligand, in some circumstances acting as “enhancers” and in other circumstances as “attenuators”.²⁸ We have previously reported β 1/2AR-activating autoantibodies from patients with postural tachycardia syndrome (POTS) facilitated β AR agonist isoproterenol-stimulated β 1/2AR activation in cultured cells in vitro, while α 1AR-activating autoantibodies from these patients partially blocked α 1AR agonist phenylephrine-induced vasoconstriction in the isolated rat cremaster arteriole assay.²⁹ The differing

allosteric effects of these autoantibodies may contribute to the pathophysiology of POTS. Using the same arteriole assay, we have now demonstrated AT1R-AAb from immunized rabbits exerted a similar antagonistic effect on Ang II-induced contractile response. Consistent with this finding, the pressor response to Ang II infusion was attenuated in immunized rabbits compared to the pre-immune baseline. It is not clear at this point if these allosteric effects will be consistent for a given autoantibody-receptor complex or whether a variety of autoantibodies directed toward nearby structures will provide a kaleidoscope of effects when studied in detail.

Perspectives

We have developed a rabbit model of AT1R-AAb-mediated hypertension. This model will be useful in studying autoimmune hypertensive pathophysiology as well as therapeutic interventions. We used a reconstructed peptide that is capable of binding to the antibodies but with conferred protection against proteolysis. This peptide therefore serves as a decoy and prevents the autoantibody from binding to the cell membrane receptor and keeping it from activation. This would lead to clearance of the decoy peptide-autoantibody complex and potentially lead to the body developing “tolerance” to this epitope and suppression of autoantibody production. Pharmacological blockade of pathological autoantibodies with novel peptide inhibitors will set the stage for developing a new strategy for the prophylaxis and/or treatment for patients who harbor these autoantibodies and presumably would leave the targeted receptor free for normal physiological function.

Acknowledgments

Source of Funding: This work was supported in part by grants from a Veterans Affairs Merit Review Award (D.C.K. and X.Y.), National Heart, Lung, and Blood Institute HL56267 (M.W.C. and D.C.K.), American Heart Association Postdoctoral Fellowship (H.L.), and the Talley Research Award of the Harold Hamm Diabetes Center at the University of Oklahoma (X.Y.).

References

1. Cowley AW Jr, Nadeau JH, Baccarelli A, Berecek K, Fornage M, Gibbons GH, Harrison DG, Liang M, Nathanielsz PW, O'Connor DT, Ordovas J, Peng W, Soares MB, Szyf M, Tolunay HE, Wood KC, Zhao K, Galis ZS. Report of the national heart, lung, and blood institute working group on epigenetics and hypertension. *Hypertension*. 2012; 59:899–905. [PubMed: 22431584]
2. Xia Y, Kellems RE. Angiotensin receptor agonistic autoantibodies and hypertension: Preeclampsia and beyond. *Circ Res*. 2013; 113:78–87. [PubMed: 23788505]
3. Luft FC. Activating autoantibodies and cardiovascular disease. *Physiology (Bethesda)*. 2013; 28:254–261. [PubMed: 23817800]
4. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin at1 receptor. *J Clin Invest*. 1999; 103:945–952. [PubMed: 10194466]
5. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjogren KG, Hjalmarson A, Muller-Esterl W, Hoebeke J. Autoantibodies against the angiotensin receptor (at1) in patients with hypertension. *J Hypertens*. 2000; 18:945–953. [PubMed: 10930193]
6. Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against at1-receptor and alpha1-adrenergic receptor in patients with hypertension. *Hypertens Res*. 2002; 25:641–646. [PubMed: 12358154]

7. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G. Angiotensin ii type 1-receptor activating antibodies in renal-allograft rejection. *N Engl J Med*. 2005; 352:558–569. [PubMed: 15703421]
8. Rossitto G, Regolisti G, Rossi E, Negro A, Nicoli D, Casali B, Toniato A, Caroccia B, Seccia TM, Walther T, Rossi GP. Elevation of angiotensin-ii type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma. *Hypertension*. 2013; 61:526–533. [PubMed: 23248149]
9. Kem DC, Li H, Velarde-Miranda C, Liles C, Vanderlinde-Wood M, Galloway A, Khan M, Zillner C, Benbrook A, Rao V, Gomez-Sanchez CE, Cunningham MW, Yu X. Autoimmune mechanisms activating the angiotensin at1 receptor in ‘primary’ aldosteronism. *J Clin Endocrinol Metab*. 2014; 99:1790–1797. [PubMed: 24552217]
10. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: Correlation with disease severity. *Hypertension*. 2010; 55:386–393. [PubMed: 19996068]
11. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. *Nat Med*. 2008; 14:855–862. [PubMed: 18660815]
12. Fu ML, Herlitz H, Wallukat G, Hilme E, Hedner T, Hoebeke J, Hjalmarson A. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. *Lancet*. 1994; 344:1660–1663. [PubMed: 7527885]
13. Luther HP, Homuth V, Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. *Hypertension*. 1997; 29:678–682. [PubMed: 9040456]
14. Wenzel K, Haase H, Wallukat G, Derer W, Bartel S, Homuth V, Herse F, Hubner N, Schulz H, Janczikowski M, Lindschau C, Schroeder C, Verlohren S, Morano I, Muller DN, Luft FC, Dietz R, Dechend R, Karczewski P. Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension. *PLoS One*. 2008; 3:e3742. [PubMed: 19011682]
15. Zhou Z, Liao YH, Wei Y, Wei F, Wang B, Li L, Wang M, Liu K. Cardiac remodeling after long-term stimulation by antibodies against the alpha1-adrenergic receptor in rats. *Clin Immunol*. 2005; 114:164–173. [PubMed: 15639650]
16. Wenzel K, Wallukat G, Qadri F, Hubner N, Schulz H, Hummel O, Herse F, Heuser A, Fischer R, Heidecke H, Luft FC, Muller DN, Dietz R, Dechend R. Alpha1a-adrenergic receptor-directed autoimmunity induces left ventricular damage and diastolic dysfunction in rats. *PLoS One*. 2010; 5:e9409. [PubMed: 20195525]
17. Fischer PM. The design, synthesis and application of stereochemical and directional peptide isomers: A critical review. *Curr Protein Pept Sci*. 2003; 4:339–356. [PubMed: 14529528]
18. Wenzel K, Rajakumar A, Haase H, Geusens N, Hubner N, Schulz H, Brewer J, Roberts L, Hubel CA, Herse F, Hering L, Qadri F, Lindschau C, Wallukat G, Pijnenborg R, Heidecke H, Riemekasten G, Luft FC, Muller DN, Lamarca B, Dechend R. Angiotensin ii type 1 receptor antibodies and increased angiotensin ii sensitivity in pregnant rats. *Hypertension*. 2011; 58:77–84. [PubMed: 21576625]
19. Felix SB, Staudt A. Immunoabsorption as treatment option in dilated cardiomyopathy. *Autoimmunity*. 2008; 41:484–489. [PubMed: 18781476]
20. Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Long-term benefits of immunoabsorption in beta(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. *Eur J Heart Fail*. 2012; 14:1374–1388. [PubMed: 22892122]
21. Jahns R, Schlipp A, Boivin V, Lohse MJ. Targeting receptor antibodies in immune cardiomyopathy. *Semin Thromb Hemost*. 2010; 36:212–218. [PubMed: 20414837]
22. Haberland A, Wallukat G, Dahmen C, Kage A, Schimke I. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. *Circ Res*. 2011; 109:986–992. [PubMed: 21868696]
23. Wallukat G, Haberland A, Berg S, Schulz A, Freyse EJ, Dahmen C, Kage A, Dandel M, Vetter R, Salzsieder E, Kreutz R, Schimke I. The first aptamer-apheresis column specifically for clearing blood of beta1-receptor autoantibodies. *Circ J*. 2012; 76:2449–2455. [PubMed: 22850243]

24. Mason JM. Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. *Future Med Chem.* 2010; 2:1813–1822. [PubMed: 21428804]
25. Munch G, Boivin-Jahns V, Holthoff HP, Adler K, Lappo M, Truol S, Degen H, Steiger N, Lohse MJ, Jahns R, Ungerer M. Administration of the cyclic peptide cor-1 in humans (phase i study): Ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. *Eur J Heart Fail.* 2012; 14:1230–1239. [PubMed: 22968742]
26. Taylor M, Moore S, Mayes J, Parkin E, Beeg M, Canovi M, Gobbi M, Mann DM, Allsop D. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for alzheimer's disease. *Biochemistry.* 2010; 49:3261–3272. [PubMed: 20230062]
27. Bloom O, Cheng KF, He M, Papatheodorou A, Volpe BT, Diamond B, Al-Abed Y. Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. *Proc Natl Acad Sci U S A.* 2011; 108:10255–10259. [PubMed: 21646518]
28. Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape SY, Byrne DW, Robertson D. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. *Circulation.* 2005; 111:1574–1582. [PubMed: 15781744]
29. Li H, Yu X, Liles C, Khan M, Vanderlinde-Wood M, Galloway A, Zillner C, Benbrook A, Reim S, Collier D, Hill MA, Raj SR, Okamoto LE, Cunningham MW, Aston CE, Kem DC. Autoimmune basis for postural tachycardia syndrome. *Journal of the American Heart Association.* 2014; 3:e000755. [PubMed: 24572257]

Novelty and Significance

What Is New?

Immunization of rabbits with a peptide from the angiotensin AT1 receptor (AT1R) produced AT1R-activating autoantibody-mediated hypertension, which was blocked by a proteolytically stable decoy peptide that specifically targets the AT1R autoantibodies.

What Is Relevant?

AT1R-activating autoantibodies have been reported in patients with hypertensive disorders including preeclampsia, malignant and refractory hypertension, and primary aldosteronism.

Summary

This study supports a pathophysiological role of AT1R-activating autoantibodies in hypertension. Pharmacological blockade of pathological autoantibodies with peptide inhibitors may open a new avenue for developing novel therapeutic approaches for patients who harbor these autoantibodies.

Figure 1. Chemical structure and serum stability of the AT1R epitope peptide (A & C) and epitope-mimetic RID peptide (B & D). There was a rapid proteolysis of the L-amino acid peptide AFHYESQ in human serum in vitro with complete degradation by 45 min, while the RID peptide d-QSEYHFA remained intact at 2 hrs and 80% was still intact at 24 hrs.

Figure 2.

Effect of the RID peptide on AT1R-AAb-induced elevation of blood pressure (A) and heart rate (B) in the rabbit. Rabbits ($n=6$) were immunized with the AT1R epitope peptide, and boosted at 2 and 4 weeks. At 6 weeks, there was a significant elevation in mean arterial pressure (MAP) and heart rate compared to the pre-immune state. Injection of the immunized animals with the RID peptide (1 mg/kg) at 6 weeks reversed elevated MAP and heart rate to their baseline levels.

Figure 3.

A, Dose effect of rabbit post-immune anti-AT1R sera on AT1R activation in transfected Chinese hamster ovary (CHO) cells. Dilutions as low as 1:200 produced a significant increase in AT1R activity compared with the buffer alone. **p<0.01 vs. buffer baseline, n=3. B, Effect of the RID peptide and losartan on AT1R-AAb-induced AT1R activation in transfected CHO cells. Compared to the pre-immune sera, the post-immune sera (1:100) from the 6 rabbits led to significant activation of AT1R, which was suppressed by the RID

peptide and AT1R blocker losartan (10 μ M). Data are expressed as percentage of buffer baseline.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 4.

A, Dose effect of rabbit post-immune anti-AT1R sera on vasoconstriction in the rat cremaster arteriole assay. There was significant contractile activity in the post-immune sera at dilutions from 1:10 to 1:125. * $p < 0.05$, ** $p < 0.01$ vs. buffer baseline, $n = 4$. B, Effect of the RID peptide and losartan on AT1R-AAb-induced contraction of isolated rat cremaster arterioles. Compared to the pre-immune sera, the post-immune sera (1:100) from the 6 rabbits induced significant vasoconstriction, which was effectively blocked by the RID peptide and losartan (10 μ M). Data are expressed as percentage of buffer baseline.

Figure 5.

Effect of AT1R-AAb on Ang II-induced pressor response in the rabbit (A) and in isolated rat cremaster arterioles (B). Infusion of the 6 rabbits with increasing doses of Ang II (10, 100 and 500 ng/kg) before immunization caused significantly greater increases in MAP than those observed at 6 weeks post immunization. In the cremaster vasoconstriction assay, rabbit anti-AT1R sera (1:100) shifted the Ang II dose response curve to the right, demonstrating an allosteric antagonistic effect of AT1R-AAb. * $p < 0.05$, ** $p < 0.01$, $n = 3$.

Table 1
Comparison of blood chemistry values from the 6 rabbits before and after immunization

Analyte	Pre-immune	Post-immune	P value
Sodium (mEq/L)	141±2	144±3	0.10
Potassium (mEq/L)	3.7±0.1	3.5±0.3	0.13
Chloride (mEq/L)	100±3	103±4	0.12
Hematocrit (%)	34±2	35±3	0.49
Hemoglobin (g/dL)	11.7±0.6	11.9±1.1	0.46